The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease - PubMed
The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Latika Sibal et al. Curr Cardiol Rev. 2010 May.
Abstract
Endothelium plays a crucial role in the maintenance of vascular tone and structure. Endothelial dysfunction is known to precede overt coronary artery disease. A number of cardiovascular risk factors, as well as metabolic diseases and systemic or local inflammation cause endothelial dysfunction. Nitric oxide (NO) is one of the major endothelium derived vaso-active substances whose role is of prime importance in maintaining endothelial homeostasis. Low levels of NO are associated with impaired endothelial function. Asymmetric dimethylarginine (ADMA), an analogue of L-arginine, is a naturally occurring product of metabolism found in human circulation. Elevated levels of ADMA inhibit NO synthesis and therefore impair endothelial function and thus promote atherosclerosis. ADMA levels are increased in people with hypercholesterolemia, atherosclerosis, hypertension, chronic heart failure, diabetes mellitus and chronic renal failure. A number of studies have reported ADMA as a novel risk marker of cardiovascular disease. Increased levels of ADMA have been shown to be the strongest risk predictor, beyond traditional risk factors, of cardiovascular events and all-cause and cardiovascular mortality in people with coronary artery disease. Interventions such as treatment with L-arginine have been shown to improve endothelium-mediated vasodilatation in people with high ADMA levels. However the clinical utility of modifying circulating ADMA levels remains uncertain.
Keywords: Asymmetric dimethylarginine; cardiovascular disease.; endothelial.
Figures

Overview of pathways of synthesis and metabolism of ADMA. Methylation of arginine residues within peptides occurs through N-methyltransferases, protein arginine N-methyltransferase-1 (PRMT-1). S-adenosylmethionine (SAM) is the methyl donor, changing to S-adenosylhomocysteine (SAH). Proteolytic breakdown of the proteins leads to the generation of ADMA and N-monomethyl-L-arginine (L-NMMA) within cells, and is detectable in the circulation. ADMA is an inhibitor of endothelial nitric oxide synthase (eNOS) by competing with its substrate L-arginine thus impairing nitric oxide (NO) production, thus leading to endothelial dysfunction and subsequently atherosclerosis. ADMA is eliminated partly via urinary excretion but mainly via metabolism by the enzyme dimethylarginine dimethylaminohydrolase (DDAH) to citrulline and dimethylamine.
Similar articles
-
Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH. Böger RH. Clin Chem Lab Med. 2003 Nov;41(11):1467-72. doi: 10.1515/CCLM.2003.225. Clin Chem Lab Med. 2003. PMID: 14656027 Review.
-
Böger RH, Maas R, Schulze F, Schwedhelm E. Böger RH, et al. Clin Chem Lab Med. 2005;43(10):1124-9. doi: 10.1515/CCLM.2005.196. Clin Chem Lab Med. 2005. PMID: 16197309 Review.
-
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
Böger RH. Böger RH. Cardiovasc Res. 2003 Oct 1;59(4):824-33. doi: 10.1016/s0008-6363(03)00500-5. Cardiovasc Res. 2003. PMID: 14553822 Review.
-
[Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R, Cibulka R, Rajdl D, Racek J. Siroká R, et al. Vnitr Lek. 2006 Mar;52(3):249-55. Vnitr Lek. 2006. PMID: 16722156 Review. Czech.
-
Böger RH, Bode-Böger SM. Böger RH, et al. Semin Thromb Hemost. 2000;26(5):539-45. doi: 10.1055/s-2000-13210. Semin Thromb Hemost. 2000. PMID: 11129410 Review.
Cited by
-
Moonen RM, Huizing MJ, Cavallaro G, González-Luis GE, Bas-Suárez P, Bakker JA, Villamor E. Moonen RM, et al. Int J Mol Sci. 2014 Dec 23;16(1):19-39. doi: 10.3390/ijms16010019. Int J Mol Sci. 2014. PMID: 25546385 Free PMC article.
-
Menzel D, Haller H, Wilhelm M, Robenek H. Menzel D, et al. Eur J Nutr. 2018 Mar;57(2):557-568. doi: 10.1007/s00394-016-1342-6. Epub 2016 Nov 5. Eur J Nutr. 2018. PMID: 27817128 Free PMC article. Clinical Trial.
-
Gillis K, Stevens KK, Bell E, Patel RK, Jardine AG, Morris STW, Schneider MP, Delles C, Mark PB. Gillis K, et al. Clin Kidney J. 2018 Aug;11(4):532-539. doi: 10.1093/ckj/sfx158. Epub 2018 Feb 6. Clin Kidney J. 2018. PMID: 30094018 Free PMC article.
-
Ntlahla EE, Mfengu MM, Engwa GA, Nkeh-Chungag BN, Sewani-Rusike CR. Ntlahla EE, et al. Afr Health Sci. 2021 Sep;21(3):1172-1184. doi: 10.4314/ahs.v21i3.26. Afr Health Sci. 2021. PMID: 35222580 Free PMC article.
-
Endothelial function in patients with atrial fibrillation.
Khan AA, Thomas GN, Lip GYH, Shantsila A. Khan AA, et al. Ann Med. 2020 Feb-Mar;52(1-2):1-11. doi: 10.1080/07853890.2019.1711158. Epub 2020 Jan 10. Ann Med. 2020. PMID: 31903788 Free PMC article. Review.
References
-
- Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med. 1986;80:33–9. - PubMed
-
- Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000;343:16–22. - PubMed
-
- Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–6. - PubMed
-
- Forstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension. 1994;23:1121–31. - PubMed
LinkOut - more resources
Full Text Sources